Lu, Xiaoyun

Targeting EGFR L858R/T790M and EGFR L858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry

Lu, X., Yu, L., Zhang, Z., Ren, X., Smaill, J. B., & Ding, K. (2018) · Medicinal Research Reviews

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 173

Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC

Yang, F., Wen, Y., Wang, C., Zhou, Y., Zhou, Y., Zhang, Z.-M., Liu, T., & Lu, X. (2022) · European Journal of Medicinal Chemistry

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 109

Recent Advance in the Design of Small Molecular Modulators of Estrogen-Related Receptors

Lu, X., Peng, L., Lv, M., & ding, K. (2012) · Current Pharmaceutical Design

Estrogen and related hormone effectsComputational Drug Discovery Methods

Cited by 28

NeoaPred: a deep-learning framework for predicting immunogenic neoantigen based on surface and structural features of peptide–human leukocyte antigen complexes

Jiang, D., Xi, B., Tan, W., Chen, Z., Wei, J., Hu, M., Lu, X., Chen, D., Cai, H., & Du, H. (2024) · Bioinformatics

vaccines and immunoinformatics approachesCancer Immunotherapy and Biomarkers

Cited by 23